These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 5394468

  • 1. [Clinical experiences with oral antidiabetic HB 419 (glibenclamide)].
    Schöffling K, Petzoldt R, Althoff-Zucker C, Beyer J, Retiene K, Böhle E, Kunkel W.
    Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1439-45. PubMed ID: 5394468
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tolazamide in the treatment of diabetes mellitus: clinical experience and review of the literature.
    Balodimos MC, Marble A.
    Curr Ther Res Clin Exp; 1971 Jan; 13(1):6-12. PubMed ID: 4992570
    [No Abstract] [Full Text] [Related]

  • 5. [Preliminary results with a new oral antidiabetic drug of the sulfanylurea series: glibenclamide or HB 419].
    Marocco F, Patrito G.
    Minerva Med; 1970 Dec 05; 61(97):5525-42. PubMed ID: 5494124
    [No Abstract] [Full Text] [Related]

  • 6. [The development of sulfonylurea late resistance].
    Angeli I.
    Med Klin; 1970 Feb 13; 65(7):306-9. PubMed ID: 4996930
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Results of oral therapy of diabetes mellitus with the new sulfonylurea tolazamide under ambulatory conditions].
    Düntsch G.
    Arzneimittelforschung; 1970 Apr 13; 20(4):575-9. PubMed ID: 5467824
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Effect and tolerance of HB 419 in out-patient treated diabetics].
    Bauer G, Kloppe W, Schubert PU.
    Arzneimittelforschung; 1969 Aug 13; 19(8):Suppl:1434-6. PubMed ID: 5394467
    [No Abstract] [Full Text] [Related]

  • 11. [Experiences with sulfonylurea tolazamide in an out-patient clinic for diabetics].
    Kanzler G, Trenkner G, Rausch-Stroomann JB.
    Arzneimittelforschung; 1968 Oct 13; 18(10):1345-8. PubMed ID: 5756166
    [No Abstract] [Full Text] [Related]

  • 12. [Our experience with Daonil. A new oral hypoglycemic agent].
    Rodriguez-Miñon JL, Arrieta F, Herrera JL.
    Diabete; 1970 Oct 13; 18(3):164-5. PubMed ID: 5472233
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Suppression of thyroid gland function by prolonged use of HB 419].
    Stötter G, Szabo J, Köhler W.
    Arzneimittelforschung; 1969 Aug 13; 19(8):Suppl:1436-9. PubMed ID: 4186530
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A clinical trial of glybenclamide (HB-419): a new oral hypoglycemic agent.
    Choudhry AS, Gomez E, McKendry JB.
    Appl Ther; 1970 May 13; 12(5):28-9. PubMed ID: 4912481
    [No Abstract] [Full Text] [Related]

  • 20. [Clinical studies on the effect of a new oral antidiabetic agent Glybenclamide (HB 419)].
    Schmitt H, Höhler H, Daweke H, Jahnke K.
    Dtsch Med Wochenschr; 1969 Apr 18; 94(16):824-9. PubMed ID: 5776707
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.